Skip to main content

Author: ICBC Staff

An Estimated 1,000 Global Cannabis Industry Senior Decision Makers To Take Part In CannX Tel Aviv 2019 Conference

The International Cannabis Business Conference would like to encourage international cannabis entrepreneurs and cannabis enthusiasts to check out the upcoming International Medical Cannabis Conference (CannX). Below is more information about the event:

The international medical cannabis conference focusing on business, technology and agriculture will take place for the fourth year in a row on September 9-10.

The conference will include a politics session focusing on the issue of medical cannabis and the upcoming election campaign.

Conference speakers will include:

  • CannX Chairman Prof. Raphael Mechoulam, THC Cannabinoid Trailblazer and Israel Prize Recipient
  • Kevin Roland, Director, Canopy Growth Corporation, Canada
  • Philippe Lucas, VP, Global Patient Research & Access, Tilray, Canada
  • Jonathan Page, Chief Science Officer, Aurora Cannabis Inc., Canada
  • Steve Hawkins, President and CEO of Horizons ETFs,Canada
  • Ziva Eger, Chief Executive of Foreign Investments & Industrial Co-operation, Israel
  • Minister of Agriculture Uri Ariel
  • Prof. Arnon Afek, Acting Chief Physician, Israeli Medical Cannabis Agency, Ministry of Health and former Director General of the Ministry of Health
  • Itai Malchior, Head of the Inter-Ministerial Committee for the Export of Medicinal Cannabis, Foreign Trade Administration, Ministry of Economy & Industry

The 4th International Medical Cannabis Conference (CannX) will take place on 9-10 September at the Expo Tel Aviv venue. The CannX experience has been refined to offer some of the most effective networking in the business and access to key opinion leaders. An estimated 1,000 senior decision makers from the entire global cannabis industry value chain are expected to participate in the international conference. Among them entrepreneurs, investors, growers, physicians, researchers, senior decision makers in medical cannabis companies, pharmacists and patients.

The conference will take place for the 4th consecutive year in partnership with Cann10, which manufactures and markets medical cannabis products and technologies and Kenes, a professional conference organizer.

CannX is the only medical cannabis conference which is accredited as a scientific conference by the European Accreditation Council for Continuing Medical Education (EACCME). This year, attendees at CannX will enjoy a more dynamic and interactive program – allowing them to participate directly in debates and discussions.

Within the main conference topics:

September 9 (Monday):

10:00 OPENING SESSION’ Uri Ariel, Minister of Agriculture

10:15 OPENING SESSION, Yossi Bornstein, Founder, Partner and Owner, Cann10, Founder, Shizim Group, Biomed holding group.

10:30 KEYNOTE LECTURE: THE CANNABINOID SYSTEM: WHERE DO WE STAND TODAY? Prof. Raphael Mechoulam, CannX Chairman, THC Cannabinoid Trailblazer and Israel Prize Recipient

11:30 SESSION: CANNABIS AND THE OPIOD EPIDEMIC, Chair: Elyad Davidson, Director, Pain Relief Unit at Hadassah Hebrew University Medical Center, Israel; David Casarett, Prof. Chief of Palliative Care, Duke University, USA; Philippe Lucas, VP of Patient Research and Access, Tilray, Canada

12:20 SESSION: THE ISRAEL MODEL: A SMALL COUNTRY, A LEADING INDUSTRY, Chair: Kobi Caspi, Co-founder and CFO, Cann10, Israel, Karina Rubinstein, Director of Business Development, Start Up Division at Israel Innovation Authority, Israel; Ziva Eger, Chief Executive of Foreign Investments & Industrial Cooperation; Amir Goldstein, Chief Operations
Officer, IMC, Israel; Tal Ben David, Head Pharmacist, GreenPharma, Israel; Liron Goldshtein, Head, Cannabis Pharmacy Dept., GreenPharma, Israel

12:20 SESSION: CANNABIS GENETICS – NEW DEVELOPMENTS, Chair: Shay Avraham Sarid, Co-Founder & CTO, Seach Medical Cannabis Group, Israel; Jonathan Page, Chief Scientist, Aurora Cannabis Inc., Canada; Arnon Heyman, CEO, Canonic Ltd., Israel

14:30 SESSION: THE IMPACT OF CANNABIS-BASED TREATMENT ON VARIOUS DISEASES – PRE-CLINICAL AND CLINICAL RESULTS, Chair: Reuven Or, Prof MD Cancer Immunotherapy & Immunobiology Research Center, Hadassah University Hospital, Israel; Yossi Tam (ENDOCANNABINOID SYSTEM IN HUMAN PHYSIOLOGY); Gurmit Singh (CBDA-ME AND PERIPHERAL NEUROPATHIC PAIN); Ruth Djaldetti (CANNABIS AND PARKINSON); Vered Hermush (DEMENTIA AND CANNABIS); Avi Priel (PAIN AND IONOTROPIC CANNABINOIDS RECEPTORS); Reuven Or and Osnat Almogi-Hazan (CANNABIS IN
CANCER)

14:30 SESSION: DIGITAL HEALTH AND CANNABIS – IS THE FUTURE HERE? BIG DATA, PREDICTION, AND ARTIFICIAL INTELLIGENCE, Chair: Gali Weinreb, Editor and Biomed correspondent, Globes, Israel; Itzhak Kurek, CEO and Co-Founder, Cannformatics Inc., USA; David Berg, President and CTO, Strainprint Technologies Ltd., Canada; Avihu Tamir, CEO, Kanabo Research, Israel

September 10 (Tuesday):

10:00 SESSION: ENTERING THE PHARMACEUTICAL INDUSTRY – HOW TO MEET PHARMA STANDARDS IN CANNABIS BASED PRODUCTS, Arnon Afek, Associate Director General, Sheba Medical Center, Acting Chief Physician, Israeli Medical Cannabis Agency, Ministry of Health, Israel; Kevin Roland, Director, CMC (Chemical Manufacturing Controls), Canopy Health Innovation, Canopy Growth Corporation, Canada; Patrick Schmitt, Molecular biologist, Co-Founder and Chief Science Officer, Farmako, Germany; Ianiv Eisenscher, Chief Product Officer, Syqe Medical, Israel; Orna Dreazen, CEO and Chairperson of the Board of Directors, Nextar Chempharma Solutions Ltd., Israel

12:00 DECISION-MAKERS PANEL – THE POLITICAL ANGLE OF THE MEDICAL CANNABIS FIELD; Moderator: Dafna Liel, Channel 12 Knesset Correspondent, Politician panelists participating will be disclosed later on.

14:00 SESSION: GLOBAL TRADE: OVERCOMING IMPORT-EXPORT BARRIERS IN A CONSTANTLY CHANGING REGULATORY ENVIRONMENT, Moderator: Lior Kenan, Chanel 13 Economics Correspondent, Israel; Itai Melchior, Senior Project Manager at Foreign Trade Administration – Ministry of Economy and Industry, Israel; Elizabeth Hatchuel, Adjunct Professor, Universidade Federal Rural do Rio de Janeiro, Brazil

16:00 SESSION: THE MEDICAL CANNABIS CAPITAL MARKET – AN ECONOMIC BUBBLE OR THE REAL THING? Moderator: Sophie Shulman, Capital Markets Editor, Calcalist, Israel, Steve Hawkins, President and CEO, Horizons ETFs, Canada; Shiry Eden, Founder and CEO, Nishot, Israel; Brenda Smith, CEO & Founder, CB Capital Concierge, Inc., USA; Ilan Gerzi, Adv., Senior Partner and Head of the Capital Markets Department, Pearl Cohen, Israel

 

Ori Alperovitz, Cann10 CEO: “In the past decade, medical cannabis has gone through a dramatic image shift, from a dangerous drug to a legitimate plant with unique medical qualities which have yet to be fully exposed. Every year, the CannX conference draws hundreds of senior decision makers from the entire global cannabis industry value chain, who are thirsty for sources of knowledge and new investment channels within this field, to Israel.

A young and constantly evolving field, the global cannabis industry is going through frequent changes due to changing regulatory policies and scientific breakthroughs created by the medical community. Our Cann10 accelerator is always on the lookout for smart, personalized cannabis technologies spearheading the innovative cannabis arena worldwide.

Cann10 Background:

Cann10 is an international company for development and marketing of medical cannabis products and innovative technological entrepreneurship within this field. Cann10 owns and distributes the “Cannareet” brand sold in Israeli pharmacies within the new medical cannabis regulations (30% market share). Among company activities in Israel and abroad: development and promotion of medical cannabis startups within the CannXL accelerator; management of a medical cannabis entrepreneurship course in collaboration with the Technion (Israel Institute of Technology); entrepreneurship and management of scientific, technological and business conferences within the medical cannabis field in Israel and other parts of the world; partnership in factory and breeding farm establishment in a number of countries.

Is Cannabis A Constitutional Question?

By Marguerite Arnold

As the discussion about cannabis access in Europe continues to progress, albeit slowly, based on the legislative mandates of lawmakers and regulatory policies driven by medical efficacy, there is an additional conversation afoot.

Namely, is the right to access affordable medical cannabis actually something more fundamental? In two countries, Canada and Mexico, this is the discussion that has actually driven the industry forward. In Canada, the constitutional right to medical access is what created the private medical market and then the recreational one beyond that.

In Mexico, where the Supreme Court first decided that patients had a constitutional right to access the drug several years ago, this summer the Court has ordered the Ministry of Health to issue much-stalled regulations within 6 months.

How different are these drivers than what is going on in the United States and Europe right now?

Is Medical Cannabis and Or Healthcare A Human Right?

The question about how access is framed depends on the domestic debate going on around you. For example, in Germany, patient access to cannabis was first decided by a patient lawsuit via a patient seeking to grow his own medicine when obtaining it from a pharmacy was cost-prohibitive.

However, because the right to grow cannabis was not enshrined into constitutional law, this right was taken away after the law was reformed in March 2017. Now German patients, theoretically, with health conditions that qualify for cannabis can try to get it covered by their health insurance.

Since not having health insurance is against the law, the legal construct in Germany is more or less that accessing cannabis, if you can convince your doctor to prescribe it and your insurer to cover it, is a basic, fundamental right of access that comes with sovereignty and or the right to live in the country legally – details and problems along the
way notwithstanding, starting with the fact that insurers are demanding proof of medical efficacy which does not exist yet.

In Canada, as the industry has learned, patients have fought hard to protect their right to cultivate, and this has been upheld, particularly because health insurance coverage for the drug is not mandatory.

In the United States, this political point of view is unwieldy and tied up with greater discussions about how the entire insurance coverage issue turns. Universal healthcare is contentious enough. It is unlikely, in other words, that the federal Constitution will be altered as states’ have done to ensure the progress of the industry.

In Mexico, it remains to be seen how the Supreme Court mandate over the Ministry of Health will fundamentally move the industry forward. There are bank regulations that must be dealt with, all of which depend on the greater acceptance of the U.S. banks that still face an uncertain discussion about cannabis.

However, if accessing cannabis is a human right, and the health department is forced to issue regulations about its use, perhaps the financial regulatory aspects of prohibition that have long held this issue back south of the border are finally on their way out too.

About International Cannabis Business Conference

International Cannabis Business Conference events are the premier cannabis events for entrepreneurs across the globe. With events in Canada, the United States, Switzerland, Spain, and Germany the International Cannabis Business Conference is where the world meets cannabis. Find out more at InternationalCBC.com and on Twitter, Facebook, and Instagram.

Thai Surprise: Country Warned By International Bodies Over Cannabis Liberalization Plans

By Marguerite Arnold

For all of its enthusiastic entry into the legal cannabis space of late, Thailand has also caught the attention of international regulators (specifically the International Narcotics Control Board INCB). In fact, the agency recently issued a warning to the government to go slow when it comes to bucking a century of prohibition.

Thailand has already been warned that if it decriminalizes cannabis for recreational use it might also lose import privileges for certain types of medicines.

While such dire threats were not issued when Luxembourg recently made international headlines for committing to cannabis reform measures, this is also mostly driven by the reality that Thailand, unlike Luxembourg, seems to be gearing up for both an export policy and an active tourist economy.

Then again, there are three international treaties at stake – namely the 1961 Single Convention on Narcotic Drugs, the Convention on Psychotropic Substances of 1971 and the Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988.

The warning comes at a time when the excitement about Thailand proceeding with cultivation licenses is increasing, however, the Public Health Ministry has yet to decide on a composition of a committee to oversee said production if not consumption downstream.

If this confusion sounds familiar, there is a reason. Every country, from Germany to Canada, has gone through a protracted, and often painful, internal and external rulemaking and implementation process.

In Germany for example, a country with a now formalized cultivation bid process, the German government seems more interested in importing flower across the border with Holland than tendering any domestically produced product for now (although a new bid round is also widely rumoured to be in the cards within the next 24 months).

In Canada, health regulators are now dealing with the extremely messy backlash due to moving too quickly into a regulated market that still allowed a major disaster like CannTrust to happen.

And those are just the “easy” examples.

South of the U.S. border, in particular, every attempt to liberalize drug policy and end the drug war has run into opposition from U.S. banks in addition to everything else. See both Mexico and Uruguay.

In summary, what Thailand is facing is no more, and no less, than official notification from bodies who have yet to catch up with the speed of events on the ground and that cannabis is still a highly stigmatized and controlled substance.

How the country adapts to such realities and learns from others now in similar circumstances (such as Greece) will be interesting to watch as another subchapter in reform now rolls into the history book.

Even in Asia.

About International Cannabis Business Conference

International Cannabis Business Conference events are the premier cannabis events for entrepreneurs across the globe. With events in Canada, the United States, Switzerland, Spain, and Germany the International Cannabis Business Conference is where the world meets cannabis. Find out more at InternationalCBC.com and on Twitter, Facebook, and Instagram.

Multiple Trump Administration Officials Speak Out Against Cannabis

Officials with the Trump administration spoke out against cannabis this week. First, the United States Surgeon General issued an advisory warning about the harms of cannabis consumption. “The legalization movement may be impacting youth perception of harm from marijuana,” the advisory stated.

The advisory was largely directed at pregnant women and adolescents and its publication will be partially funded by a $100,000 donation from President Donald Trump’s salary. It did not take long for the cannabis community to take issue with the approach that the United States Surgeon General is pursuing.

“It has long been acknowledged that cannabis is a mood-altering substance with some risk potential. In fact, it is precisely because marijuana use may pose potential risks to certain consumers — for example, adolescents or people with a family history of psychiatric illness — that NORML believes that lawmakers should regulate it accordingly.” NORML‘s Executive Director Erik Altieri stated in a press release in reaction to the Surgeon General’s advisory.

Altieri went on to say, “Our current model of federal prohibition represents the utter lack of control over any aspect of marijuana or the marijuana market. The Surgeon General’s time would be better spent advocating for a legally and tightly regulated cannabis market – one in which we educate Americans about the potential harms and benefits of cannabis through evidence-based public education campaigns – rather than through fear-mongering.”

Later in the day Trump cabinet official Alex Azar (Health and Human Services) was on Fox Business promoting the advisory, but in the process, inadvertently made the case for a regulated cannabis industry when he himself pointed out that the unregulated cannabis industry doesn’t have consumer labels, which would obviously help with addressing concerns about public health education.

Today’s comments by members of the Trump administration were well summed up by Morgan Fox from the National Cannabis Industry Association, as reported by Marijuana Moment:

“Despite a lot of misinformation and selective analysis being promoted by the surgeon general and HHS today, pretty much everything they said has bolstered the case for making cannabis legal and regulated at the federal level,” Morgan Fox, media relations director for the National Cannabis Industry Association, told Marijuana Moment. “Research, honest fact-based education, and effective public health resource allocation are all stymied by prohibition.”

About the International Cannabis Business Conference

International Cannabis Business Conference events are the premier cannabis events for entrepreneurs across the globe. With events in Canada, the United States, Switzerland, Spain, and Germany the International Cannabis Business Conference is where the world meets cannabis. Find out more at InternationalCBC.com and on Twitter, Facebook, and Instagram.

Trump Administration Wants Public Feedback Regarding International Cannabis Rescheduling

Back in March the United States Food and Drug Administration initially requested input from the public regarding international cannabis policy. The public input was meant to help the U.S. Department of Health and Human Services be prepared when working with the United Nations (U.N.).

At the time it was speculated that the U.N.’s Commission on Narcotic Drugs may be voting on cannabis recommendations, and thus the United States needed to be prepared to present its position. However, a vote never materialized.

The Food and Drug Administration is now re-opening a public comment period for the same matter. People will have a 30-day window in which to provide their comment(s), as first reported by Kyle Jaeger at Marijuana Moment:

The new notice about the move to take more public input is set to be published on Thursday. After that point, people will be able to submit comments electronically or through mail for a period of 30 days.

Rescheduling cannabis under the international treaties technically wouldn’t free up member countries to legalize it without being in strict compliance, but it would reflect an evolving understanding of the plant within one of the world’s most influential intergovernmental organizations. And even the UN’s current restrictive status for cannabis hasn’t stopped Canada and Uruguay from moving forward to end prohibition.

It will be very interesting to see what the Trump administration’s position ultimately ends up being. President Trump has made multiple statements in favor of federal reform over the years, both prior to becoming president and while in office, however, comprehensive reform has yet to occur.

Cannabis reform at the international level is way overdue. Canada and Uruguay have both legalized cannabis for adult-use and other countries such as Luxembourg are likely to follow in the not-to-distant-future. The international community needs to embrace the cannabis industry, not prohibit it.

International cannabis policy and industry will be at the top of the agenda at the upcoming International Cannabis Business Conference in beautiful Vancouver, British Columbia September 15-16. Whether you are a seasoned industry veteran or someone just starting to look into the endless opportunities that exist in the cannabis space, make sure to buy your tickets today and join us in Vancouver!

About the International Cannabis Business Conference

International Cannabis Business Conference events are the premier cannabis events for entrepreneurs across the globe. With events in Canada, the United States, Switzerland, Spain, and Germany the International Cannabis Business Conference is where the world meets cannabis. Find out more at InternationalCBC.com and on Twitter, Facebook, and Instagram.

US Cannabis Legalization: Sparking A Wave Of Liberalization Abroad

By: David Wenger

In the United States, we are seeing unprecedented momentum toward legalization of cannabis. 2019 has been a historic year for reform at the federal and state levels. As the US moves closer to legalizing cannabis, the rest of the world watches. And as the US reconciles federal cannabis legalization with international drug treaty obligations, a transformational precedent will be set.

After summarizing recent progress in the US, this article discusses how the US may harmonize federal legalization with international treaty obligations and the likely resulting impact abroad.

Unprecedented Progress Towards US Federal Cannabis Reform

At the federal level in the US, historic progress is being made in the 116th Congress toward legalizing cannabis. For the first time in more than three years, on June 20 the full US House of Representatives voted on a cannabis measure. The House passed by a large majority (267-165) the Blumenauer-McClintock-Norton Amendment (1) which would protect the legal cannabis industry from DOJ action. (2) A Senate vote is expected after the August summer recess.

Prospects are high for near-term passage of the SAFE Banking Act of 2019, which would protect banks, related entities, and insurers servicing cannabis companies from federal interference. The House version (3) has 206 co-sponsors, (4) just short of the 218 total votes required. The House Financial Services Committee voted 45-15 on March 28 to advance the banking bill to the full House for a vote. (5) The Senate version (6) has 31 co-sponsors, (7) nearly one-third of the Senate.

The Senate Committee on Banking, Housing, and Urban Affairs held a public hearing on the SAFE Banking Act on July 23. (8) After the hearing, Senator Cory Gardner (R-CO) said he was confident of sufficient support in the Senate: “[I]t would pass with majority support and I think it would have a majority of Republicans voting for it as well.” (9) On July 31, the Republican Chair of the Senate Banking Committee, Sen. Mike Crapo (ID), called for ending banking restrictions on cannabis companies. (10) Through the SAFE Banking Act, Congress has an opportunity to not only protect banks and insurers that would serve the industry but also protect US stock exchanges that would list US cannabis companies. (11)

This Congress has been described as the “most marijuana-friendly Congress in history.” (Tom Angell). (12) Justin Strekal, NORML’s political director, said: “Congress has never moved this far, this fast on marijuana policy, period.” (13) Only seven months into this Congress, there have already been seven cannabis hearings. (14)

Previously-introduced federal bills are gaining support, as new federal legislation is introduced. (15) Bills such as the STATES Act (16) and the Marijuana Freedom Opportunity Act (17) are joined by recent bills such as one filed on July 31 by the second-highest ranking Democratic senator, Dick Durban (IL). (18) Democratic presidential contenders Sen. Kamala Harris (D-CA), Sen. Cory Booker (D-NJ), and Sen. Elizabeth Warren (D-MA), and House Judiciary Committee chair Rep. Jerrold Nadler (D-NY) have all sponsored legislation to legalize cannabis. (19)

Republican Senate Majority leader Mitch McConnell has not publicly supported federal cannabis reform (he remains an unknown for passage of the SAFE Banking Act). However, an interesting dynamic has developed. Senator McConnell has expended significant political capital to pass the Farm Bill legalizing hemp in December 2018, for some of his staunchest supporters in the Kentucky hemp industry. (20) But the FDA has not yet acted to provide regulatory pathways for many hemp-derived products. (21) Senate Democrats, such as Senators Ron Wyden and Jeff Merkley (both OR), and representatives on the House Small Business Committee, have already publicly urged the FDA to move forward. (22) Democrats in Congress focused on legalizing cannabis could join forces with McConnell and his Republican counterparts to urge the FDA to move forward, in exchange for McConnell and his allies agreeing to tacitly support or at least stand down from opposing federal cannabis legalization.

While Democratic presidential candidates challenge each other over cannabis reform credibility and who will most strongly support legalization, (23) President Trump waits for an opportune moment to indicate his support, for maximum political advantage. He will not go unchallenged on cannabis reform in the election runup. And he has given every indication in public and in known private conversations of his views on States’ rights with regard to cannabis reform. (24)

Significant Progress At The US States Level

At the state level, across the country there is also significant progress toward reform of medical and adult-use legislation. While there have been setbacks where legislators failed to implement the public will—including in New York where Governor Cuomo did not timely and adequately support adult-use legalization (25) and in New Jersey with opposition from some legislators whose constituents suffer the most from the war on drugs (26) —states such as Illinois and Michigan have seized an opportunity to implement pragmatic, corrective, inclusive adult-use legislation.

In 2020, Illinois (the first state to legalize adult-use through the legislature) and Michigan will have two large urban areas (metro Chicago and Detroit, combined population of 14 million) with legalized adult-use marketplaces. They will garner enormous tax revenues, and in time eclipse Colorado which has already collected more than $1 billion in cannabis tax revenues. (27) In Massachusetts, the marketplace is expanding, reaching more than $140 million in the first six months and expected to reach up to $500 million this year, (28) joining states like California, Nevada, Washington, and Oregon selling billions of dollars of legal cannabis. In states like Maine and Vermont, where adult-use cannabis is legal but not sold in regulated, state-revenue-generating stores, officials are seriously discussing a legalized, regulated marketplace. (29) States such as Florida and Oklahoma are seeing rapid expansion of their medical cannabis programs. (30) Opposition to sensible cannabis reform is largely based on ignorance or is financially motivated – in addition to the enormous tax revenues regulated markets are realizing, social impacts in legalized adult-use states have been at worst neutral and generally positive, with reports of
falling crime rates, (31) reduced youth usage, (32) reduced alcohol intake, (33) and significant reductions in prescription medication usage especially opioids. (34)

Adult-Use Cannabis Is Strictly Prohibited Under The UN Single Convention

As the US progresses towards legalization on the federal level, with growing state marketplaces, examination is warranted of the US’ international obligations under the 1961 UN Single Convention on Narcotic Drugs (the “Single Convention,” as amended by the 1972 Protocol). (35) Under Article 4 of the Single Convention, (36) the production, manufacture, export, import, distribution of, trade in, use and possession of cannabis is expressly limited “exclusively to medical and scientific purposes.” (37) Adult-use cannabis is strictly prohibited. Cannabis is placed under the strictest of the control schedules; it is considered among the most dangerous of all psychoactive substances under international control. (38)

Advances in global cannabis legislative reform contrary to the Single Convention have not gone unnoticed by the International Narcotics Control Board (“INCB,” an independent body that monitors Governments’ compliance with international drug control treaties). (39) INCB has proclaimed that Canada’s legalization of adult-use cannabis is “inconsistent” with the Convention. (40) The INCB has also said that existing drug treaties provide zero “wiggle room,” such that the strict prohibition against non-medical use applies fully to states within federal structures of government: namely, US states legalizing adult-use is inconsistent with Convention obligations. (41) In response, US officials have argued that since the cultivation, trade, and possession of cannabis remain criminal offenses under US federal law, the federal government as a State party is not in breach. (42)

Reconciling US Federal Legalization With The Single Convention: Inter Se Modification

While a federalism-grounded distinction may be acceptable for now, the US is unlikely to legalize cannabis federally for adult-use, as Canada has, without addressing its Single
Convention obligations. The US was the chief architect of the Convention, including placing cannabis under the strictest control measures. (43) The US government has long been the most ardent champion of the drug treaties, and the foremost proponent of full and vigorous implementation. (44) When Congress revises federal law to formally accommodate regulated cannabis, the federal versus states legislative distinction will no longer be possible. (45)

Revision of the UN Single Convention to accommodate an updated federal regulatory regime in the US allowing for adult-use cannabis would be difficult. Although formal mechanisms for revision exist, the reality is no substantive changes would likely be made on anything other than non-controversial issues. An amendment of the schedules to remove cannabis would require a recommendation by the WHO’s Expert Committee on Drug Dependence followed by a majority vote by 53 member States (46) of the UN Commission on Narcotic Drugs. (47)

A more likely alternative through which the US may reconcile its Convention obligations is by inter se modification permitted under Article 41 of the Vienna Convention on the Law of Treaties (“VCLT”). (48) Under the inter se modification option, like-minded parties may enter into inter se agreements permitting the production, trade and consumption of cannabis for non- medical and non-scientific purposes while remaining compliant with the Convention. A Swansea University report titled “Balancing Treaty Stability and Change: Inter se modification of the UN drug control conventions to facilitate cannabis regulation” (March 2018) explores the rationale, legitimacy, and feasibility of the inter se option for modification of Convention obligations. (49)

Under Article 41 of the VCLT, inter se modification is permissible if: (a) ‘the possibility of such a modification is provided for by the treaty’ or (b) when ‘the modification is question is not prohibited by the treaty and (i) does not affect the enjoyment by the other parties of their rights under the treaty or the performance of their obligations; or (ii) does not relate to a provision, derogation from which is incompatible with the effective execution of the object and purpose of the treaty as a whole.’ (50) In other words, because inter se modification is not provided for by the Convention, it would be available under VCLT Article 41 if enjoyment by the other parties of their rights and performance of their obligations is not affected, or if the effective execution of the object and purpose of the treaty as a whole would not be immediately compromised if one or more parties decide to regulate the sale and supply of cannabis for adult-use purposes.

An inter se agreement would need to be based on domestic markets that are isolated from non-parties to the inter se agreement. (51) A strictly controlled legal regulated market in some jurisdictions is likely to prove more effective in preventing the illicit export of cannabis from those regulated jurisdictions in comparison to the current situation because state controls over the substance are likely to be tighter and more widely respected than is currently the case. (52) Thus, a legally regulated market existing in states that are parties to the inter se agreement would not only not adversely affect non-parties to that agreement, but may well benefit non-parties.

The Swansea University report posits that the option of inter se modification holds enormous promise and merits careful consideration for application by like-minded States. (53) The report concludes that the possibility of inter se modification was specifically designed to find a balance between the stability of treaty regimes and the necessity of change in absence of consensus in order to respond to the changing social conditions in member States. (54) The report argues that the circumstances in which the UN drug control treaty regime finds itself today—systemic challenges and inconsistencies, increasing tensions with State practices, huge political and procedural obstacles to amendments, and unilateral escape attempts—merit careful consideration of the inter se modification option. (55)

Modification Of Convention Obligations Will Spark A Wave Of Legalization

When the US Congress is seriously considering legalizing cannabis federally, perhaps within 12 to 18 months, the entire North America will be close to having legal adult-use cannabis. As early as September 2019, the Mexico Senate will be discussing legalizing cannabis and the Senate has set a deadline of October 25, 2019 to approve new cannabis legislation. (56) Thus, a distinct possibility emerges of an inter se agreement negotiated amongst the North American nations that allows for regulated cannabis commerce within and between them, but also consistent with Single Convention obligations.

Should North American nations work toward entering an inter se agreement regulating cannabis commerce amongst themselves, that would spark a wave of cannabis legalization across Europe and elsewhere. Countries such as Germany, Switzerland, Spain, Portugal, the Czech Republic, and other EU nations, along with Colombia, Israel, Thailand, and many others, could very likely want to join such an agreement, laying the foundation for a global cannabis industry. The US started and fueled the global war on marijuana; when the US stands down, much of the rest of the world led by Europe will follow suit. The EU market for cannabis will be enormous – forecasted at €123B by 2028, including a €65 billion adult-use market. (57) Progress is already being seen in Europe toward legalization, including advances in medical cannabis legislation throughout the continent, (58) Swiss and French government advisory commissions calling for adult-use legalization, (59) support for legalization among rising German political parties, (60) and Luxembourg poised to enact adult-use legalization. (61) But in Europe, major progress awaits what will happen across the Atlantic.

***
The trajectory is clear, even if the timing is uncertain. As legalization advances, and the cannabis industry spreads from the Americas to Europe and beyond, the future of global cannabis commerce will present formidable challenges but also incredible opportunities for those with the foresight and ability to execute on a generational opportunity.

Citations

1 H. Amdnt. 398. https://www.congress.gov/amendment/116th-congress/house-amendment/398/text.
2 http://clerk.house.gov/evs/2019/roll370.xml; https://www.forbes.com/sites/tomangell/2019/06/20/congress-votes-to-block-feds-from-enforcing-marijuana-laws-in-legal-states/#74018cf84b62. Aaron Smith, executive director of the National Cannabis Industry Association, called the vote “without a doubt the biggest victory for federal cannabis
policy reform to date, and a hopeful sign that the harmful policies of marijuana prohibition will soon be a relic of the past.” Id.
3 https://www.congress.gov/bill/116th-congress/house-bill/1595/text.
4 https://www.congress.gov/bill/116th-congress/house-bill/1595/cosponsors.
5 https://www.covfinancialservices.com/2019/04/house-financial-services-committee-passes-cannabis-banking-bill/.
6 https://www.congress.gov/bill/116th-congress/senate-bill/1200/text.
7 https://www.congress.gov/bill/116th-congress/senate-bill/1200/cosponsors.
8 https://www.natlawreview.com/article/senate-holds-public-hearing-banking-access-cannabis-industry.
9 https://www.marijuanamoment.net/watch-live-senate-committee-holds-hearing-on-resolving-marijuana-banking-issues/
10 https://www.wikileaf.com/thestash/gop-chair-end-marijuana-banking-restrictions. He said: “I think all the issues got well vetted. We now need to, I think, move forward and see if there’s some way we can draft legislation that will deal with the issue.” Id. Senator Crapo repeated this sentiment again on August 8: “There are serious questions that I
have recognized need to get resolved. I am looking at that issue on a federal level.” https://www.postregister.com/star/ news/crapo-talks-marijuana-health-care-in-grant-park/article_ecd0364d-d620-5024-b521-647e0d0e449c.html.
11 The situation now is that US cannabis companies paying millions of dollars in federal taxes, with thousands of employees in the US, and building infrastructure across the country cannot access our capital markets, but Canadian cannabis companies with no operations here and paying no federal taxes have raised billions of dollars on the US capital markets. See https://www.newcannabisventures.com/proposed-federal-legislation-could-open-major-exchanges-to-american-cannabis-companies/.
12 https://www.forbes.com/sites/tomangell/2019/07/31/this-is-the-most-marijuana-friendly-congress-in-history/#778ea5bd672f.
13 Id.
14 Id. On June 19 the House Small Business Committee held a hearing on challenges for small business. https://www.marijuanamoment.net/watch-live-congressional-committee-discusses-challenges-for-small-marijuana-businesses/. On July 10 the House Judiciary Subcommittee on Crime, Terrorism, and Homeland Security held a hearing on ending prohibition and the racial impacts of marijuana laws. https://www.marijuanamoment.net/watch-live-congress-holds-historic-hearing-on-ending-federal-marijuana-prohibition/.
15 On August 12, the American Bar Association issued a resolution urging Congress to remove cannabis from Schedule 1 of the Controlled Substances Act to address the “regulatory quagmire” resulting from conflicting federal and state cannabis laws. https://www.marijuanamoment.net/american-bar-association-urges-congress-to-let-states-set-their-own-marijuana-policies/.
16 https://www.congress.gov/bill/116th-congress/house-bill/2093.
17 https://www.congress.gov/bill/116th-congress/senate-bill/1028.
18 https://www.marijuanamoment.net/top-democratic-senator-files-bill-to-reschedule-and-research-marijuana/; He had previously called Illinois’ medical cannabis program “almost a laughing matter.” Id.
19 https://www.harris.senate.gov/news/press-releases/harris-nadler-introduce-comprehensive-marijuana-reform-legislation; https://www.booker.senate.gov/?=press_release&id=892;
https://www.warren.senate.gov/newsroom/press-releases/senators-warren-and-gardner-reintroduce-bipartisan-bicameral-legislation-to-protect-states-marijuana-policies.
20 On August 14, Senator McConnell wrote an Op-Ed stating: “Whatever obstacles Kentucky hemp farmers, processors and manufacturers might encounter as they try to take full advantage of this hemp revolution, I’ll be there to help in any way I can. https://www.marijuanamoment.net/mitch-mcconnell-checks-in-on-hemp-legalizations-progress-op-ed/.
21 As compared to other products the FDA regulates and are widely available such as pharmaceuticals, alcohol, and high-sugar food, which lead to deaths every day through overuse, there is not a single known case of a CBD- or cannabis-caused death.
22 https://www.lexology.com/library/detail.aspx?g=048bd5f8-3704-4583-811d-ab6fa4d251d4; https://www.marijuanamoment.net/lawmakers-push-federal-agencies-to-free-up-the-cbd-industry/
23 https://www.bostonglobe.com/news/marijuana/2019/08/01/democratic-presidential-candidates-clash-marijuana-during-second-night-debate/41o10H9gUhTS8m6NEScm2H/story.html
24 See “The Green Regulatory Arbitrage,” available at https://www.newcannabisventures.com/wp-content/uploads/2018/09/The-Green-Regulatory-Arbitrage-Wenger-2018.pdf, pgs. 30-32.
25 Now, New Yorkers are spending millions of dollars buying cannabis in Massachusetts. https://www.leafly.com/news/industry/the-massachusetts-cannabis-market-is-booming-thanks-to-new-york
26 https://patch.com/new-jersey/bloomfield/new-jersey-senator-has-worries-legal-weed-do-you-agree
27 https://www.cnbc.com/2019/06/12/colorado-passes-1-billion-in-marijuana-state-revenue.html
28 https://mjbizdaily.com/massachusetts-recreational-marijuana-sales-approach-140-million/
29 https://www.pressherald.com/2019/06/27/mills-signs-marijuana-regulations-into-law/; https://mjbizdaily.com/vermont-house-committee-moves-commercial-adult-use-marijuana-bill-forward/.
30 https://mjbizdaily.com/medical-marijuana-market-growth-with-oklahoma-and-florida-leading/.
31 https://www.forbes.com/sites/janetwburns/2018/01/16/violent-crime-has-fallen-in-border-states-with-legal-cannabis-study/.
32 https://www.marijuanamoment.net/federal-data-shows-youth-marijuana-use-isnt-increasing-under-legalization/,
33 https://www.forbes.com/sites/thomaspellechia/2018/01/22/alcohol-sales-dropped-15-percent-in-states-with-medical-marijuana-laws/.
34 https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-019-0278-6; https://drugabuse.com/study-medical-marijuana-cuts-use-of-prescription-drugs/; Tom Adams, managing director of preeminent cannabis industry intelligence data firm, BDS Analytics, told me that the most eye-opening statistic in his years of analyzing the cannabis industry is the degree of the use of cannabis as a replacement for traditional medication.
35 https://www.unodc.org/documents/commissions/CND/Int_Drug_Control_Conventions/Ebook/The_International Drug_Control_Conventions_E.pdf. Two additional other international treaties prohibit commerce in cannabis for recreational purposes by virtue of the scheduling of cannabis under the Single Convention – the Convention on Psychotropic Substances (1971) and the Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances (1998). Id.
36 Signed by 186 member states, https://treaties.un.org/Pages/ViewDetails.aspx?src=TREATY&mtdsg_no=VI-18&chapter=6&lang=en.
37 Id. at pg. 30.
38 http://fileserver.idpc.net/library/stability_change-inter_se_mofication_gdpo-tni-wola_march_2018.pdf at pg. 3. The double-listing of cannabis in the Single Convention is reflective of how strictly it is treated. Cannabis, cannabis resin, and extracts and tincture of cannabis are in Schedule I among substances that present a serious risk of abuse
and are subject to all control measures envisaged by the Convention. Cannabis and cannabis resin are also listed in Schedule IV, along with another fifteen substances that are already listed in Schedule I and are deemed particularly dangerous by virtue of what are regarded to be their harmful characteristics, risk of abuse and extremely limited
therapeutic value. Id. at pg. 36, n. 9.
39 https://www.incb.org/incb/en/about.html.
40 http://fileserver.idpc.net/library/stability_change-inter_se_mofication_gdpo-tni-wola_march_2018.pdf at 3.
41 Id. at pg. 4.
42 Id. at pg. 8.
43 Id.
44 Id.
45 Id. at pg. 9.
46 https://www.unodc.org/unodc/en/commissions/CND/Membership/Membership.html.
47 http://fileserver.idpc.net/library/stability_change-inter_se_mofication_gdpo-tni-wola_march_2018.pdf at pgs. 14, 33.
48 https://treaties.un.org/doc/Publication/UNTS/Volume%201155/volume-1155-I-18232-English.pdf at pg. 342.
49 http://fileserver.idpc.net/library/stability_change-inter_se_mofication_gdpo-tni-wola_march_2018.pdf
50 https://treaties.un.org/doc/Publication/UNTS/Volume%201155/volume-1155-I-18232-English.pdf at pg. 342.
51 http://fileserver.idpc.net/library/stability_change-inter_se_mofication_gdpo-tni-wola_march_2018.pdf at 28.
52 Id.
53 Id. at pg. 34.
54 Id.
55 Id.
56 https://themazatlanpost.com/2019/07/26/mexico-recreational-use-of-marijuana-will-be-addressed-in-september-in-the-senate/; https://themazatlanpost.com/2019/08/09/mexico-senate-october-25-deadline-to-approve-marijuana-regulation/.
57 https://www.amp-eu.com/eurozone-cannabis-market-highlights-2018-and-beyond/; https://prohibitionpartners.com/wp-content/uploads/2019/07/The-European-Cannabis-Report-4th-Edition.pdf.
58 https://labiotech.eu/sponsored/medical-cannabis-europe-brexit/.
59 https://www.swissinfo.ch/eng/drug-debate-_swiss-health-commission-calls-for-legalisation-of-cannabis–/44930586; https://internationalcbc.com/french-government-tasked-commission-urges-cannabis-legalization/.
60 https://www.spiegel.de/international/germany/german-green-party-leads-in-public-opinion-polls-a-1272530.html; https://fortune.com/2019/07/19/europe-cannabis-canada/.
61 https://www.analyticalcannabis.com/articles/luxembourg-set-to-become-europes-first-recreational-cannabis-country-311735.

The Race To Conquer Cannabis Europe

Author: Marguerite Arnold

Canadian canna-businesses have had a giant head start, but they do not have a monopoly on international cannabis supply or the supply chain. And competition is on the horizon as a slew of newly budded cannabis companies are targeting Europe.

These newbies, mainly from Thailand and South Africa (and possibly Israel) are weaving their way through the thicket of international cannabis regulations right now. Spain, Portugal, Macedonia, Greece, and maybe even Poland are not too far behind, and many German ganjaprenuers are still looking for ways to get into the game

The “big boys” do not have a lock on any part of the industry, regardless of brand recognition or market presence. In the case of Canadian CannTrust, certainly that can be either a blessing or a curse. But reality is hitting the market.

Canopy is selling dronabinol to German patients (who hate it) and its German vapes to Americans – who already loved Storz and Bickel.

Everyone, in other words, who understands the market, realizes you cannot be everything to everyone.

Yes, the big public Canadians in Europe are sourcing from everywhere else, but this makes them even less price competitive in the EU. Dutcvh Bedrocan has proved that If you have a good presence on the ground in Germany and the UK, you can compete with even the deepest pocketed Canadians. But to compete, you need a good distributor in Deutschland and you need to be selling, or even better, donating cannabis products for medical studies and patient trials.

But with outdoor crops now seeded in Portugal (by Tilray), just as Luxembourg announces its own recreational rule change on the horizon, turning your eyes away from the region for “hotter fish” elsewhere is a mistake.

There are many interesting things afoot right now in Europe. Despite the distractions of the U.S. market and the scandals coming across the Atlantic, Europeans are setting a different pace.

Luxembourg has now pushed the bar for a sovereign discussion of cannabis legalization. Poland is setting up to do something. Swiss, Danish, German, and British medical trials are all on the calendar, and some have already started..

The reality for those with any sensitivity to a European wide conversation at the moment, is that, despite the occasional flare ups over medical efficacy and cost, Europe is on the brink of a breakthrough, and it seems that systems, rather than strains, are what will be the differentiator here for some time to come.

There are challenges in the European markets. Spanish health insurers are not the same as Dutch, German or the British NHS. But the medical cannabis market is rising at the same time as adult-use cannabis legalization is gaining ground in country after country.

People are tired of wasting money on a war they don’t want to fight – especially when there are so many other more looming and pressing issues. Plus there are the local economic bennies.

Europe is pondering some basic questions that everyone knows must be considered. Yes, sales are slow, but right now European cannabis sales are all a function of restrictive medical cannabis programs. Given the history of medical use leading to recreational use as seen in the USA, can full legalization be far behind? Conversations impossible just five years ago are in the room. And the industry is getting organized and stirring.

The sense of green ownership across the continent, in other words, is a great green giant that may be a bit “slower” in the offing. But it is awake and rumbling.

 

The International Cannabis Business Conference is the best industry event to learn the latest and to network with top investors and entrepreneurs. Next up: Vancouver, Canada, this September 15-16, featuring top experts in the field, PLUS a performance on a luxury yacht by Cypress Hill’s DJ Muggs at the after party. Don’t delay, purchase tickets today!

Entrepreneur Magazine: International Cannabis Business Conference Is One Of The Top Cannabis Events In The World

International Cannabis Business Conference is one of the top cannabis events in the world, according to Entrepreneur Magazine

Green Entrepreneur, the cannabis-focused division of Entrepreneur Magazine, has named the International Cannabis Business Conference as one of the “Top One Hundred Cannabis Companies” of 2019.

According to Green Entrepreneur, this list showcases businesses that “offer the industry’s most innovative, influential, and impactful products and services.” When informed that the International Cannabis Business Conference was one of only seven event companies that made the list, founder Alex Rogers had this to say: “This is an honor. We work very hard to create opportunities for canna-business and expanded legalization all over the world. Knowing that other ganjaprenuers hold our event in such high esteem is a really good feeling”. Rogers also stated that he is looking forward to the next conference in Vancouver, and is especially excited about the conference planned for Berlin in 2020, which he says will be the biggest International Cannabis Business Conference event so far.

With events in five (soon to be six) different countries, the International Cannabis Business Conference is the world’s premier B2B cannabis business conference. Visit test.internationalcbc.com for more information.

The International Cannabis Business Conference is THE industry event to learn the latest and to network with top investors, entrepreneurs, and advocates. Next up: Vancouver, British Columbia, Canada, this September 15-16. Purchase tickets today! 

Luxembourg On Track To Legalize By 2022

Written By: Marguerite Arnold

Luxembourg Throws Down Gauntlet On European Cannabis Legalization

Luxembourg is going to disrupt the European cannabis industry. This summer, Luxembourg ‘s Health Minister confirmed that the country is now moving even faster toward full cannabis legalization and plans to release its first draft of plans for legalization by the end of 2019. If this project stays on schedule, Luxembourg will have Europe’s first fully legal recreational cannabis market by the beginning of 2022. So now the race begins. If Luxembourg is going to be the “Colorado of Europe”, who will be the “Washington State”, or even the “California” of European cannabis?

A Domestic Market For Locals Or A Tourist Mecca?

Luxembourg is clearly intent on setting the recreational cannabis agenda across the continent. And while excitement is growing, investments have been slow, because there are challenges.

Yes, Luxembourg has decided to drive the cannabis agenda, which means raising this issue to the EU level and creating a deadline. However, there are a couple of things industry investors should keep in mind:

  1. Luxembourg itself is a tiny country with just over half a million residents.
  2. The cannabis legalization plan so far is being pitched as an anti-crime, public health measure. Attracting throngs of cannabis infused tourists (and their piles of cannabis infused money) isn’t on the agenda.
  3. While international cannabucks are welcome there is an increasing sense that international investors aren’t the only game in town. Local production and local ownership are on the drawing board.

What Will The Market Look Like?

There has been alot of back and forth consulting between Luxembourg and Canada. Regulatory similarities ( like a proposal to limit personal possession to 30 grams, same as in Canada) are beginning to emerge. Expect a push to allow medical cannabis patients to grow their own medicine, while recreational users will have to buy weed at the store. For some reason, the cannabis hates the idea of people being allowed to grow their own weed, even though people can make their own beer yet commercial beer makers are doing fine. The fight, er, discussion about just who will have the right to produce cannabis is just beginning.

The game is in the early stages, and the players are just getting warmed up. But Luxembourg has announced the beginnings of a plan and set a deadline. As the dominoes start to fall, we wonder: Which country will be next?

 

The International Cannabis Business Conference is the best industry event to learn the latest and to network with top investors and entrepreneurs. Next up: Vancouver, Canada, this September 15-16, featuring top experts in the field, PLUS a performance on a luxury yacht by Cypress Hill’s DJ Muggs at the after party. Don’t delay, purchase tickets today!